141 related articles for article (PubMed ID: 11275703)
21. The role of somatostatin analogs in the management of immunoproliferative disease.
Ferone D; Arvigo M; Semino C; Pivonello R; van Hagen PM; Barreca A; Minuto F
J Endocrinol Invest; 2003; 26(8 Suppl):103-8. PubMed ID: 15233223
[No Abstract] [Full Text] [Related]
22. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
23. Treatment of neuroendocrine tumors with somatostatin analogs.
Janson ET
Pituitary; 2006; 9(3):249-56. PubMed ID: 17001461
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA
Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571
[TBL] [Abstract][Full Text] [Related]
25. Perspectives of new potential therapeutic applications of somatostatin analogs.
Pawlikowski M; Melen-Mucha G
Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
[TBL] [Abstract][Full Text] [Related]
26. An immunohistochemical investigation of the expression of somatostatin receptor subtypes - should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances?
Pisarek H; Pawlikowski M; Marchlewska M; Minias R; Winczyk K
Exp Clin Endocrinol Diabetes; 2015 Jun; 123(6):342-6. PubMed ID: 25962406
[TBL] [Abstract][Full Text] [Related]
27. [Somatostatin in breast cancer].
Frati A; Antoine M; Rodenas A; Gligorov J; Rouzier R; Chéreau E
Ann Biol Clin (Paris); 2011; 69(4):385-91. PubMed ID: 21896402
[TBL] [Abstract][Full Text] [Related]
28. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
[TBL] [Abstract][Full Text] [Related]
29. Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide.
Van Den Bossche B; D'haeninck E; De Vos F; Dierckx RA; Van Belle S; Bracke M; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1022-30. PubMed ID: 15029461
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer imaging using radiolabelled somatostatin analogues.
Dalm SU; Melis M; Emmering J; Kwekkeboom DJ; de Jong M
Nucl Med Biol; 2016 Sep; 43(9):559-565. PubMed ID: 27409729
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of somatostatin.
Pyronnet S; Bousquet C; Najib S; Azar R; Laklai H; Susini C
Mol Cell Endocrinol; 2008 May; 286(1-2):230-7. PubMed ID: 18359151
[TBL] [Abstract][Full Text] [Related]
32. [Somatostatin analogs in the treatment of pancreatic cancer: utopia or feasible alternative?].
Zalatnai A; Pogány V
Orv Hetil; 2000 Oct; 141(43):2333-8. PubMed ID: 11089387
[TBL] [Abstract][Full Text] [Related]
33. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
34. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
35. The potential role of somatostatin analogues in breast cancer treatment.
Pollak M
Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
[TBL] [Abstract][Full Text] [Related]
36. Molecular modeling suggests conformational scaffolds specifically targeting five subtypes of somatostatin receptors.
Nikiforovich GV; Marshall GR; Achilefu S
Chem Biol Drug Des; 2007 Mar; 69(3):163-9. PubMed ID: 17441902
[TBL] [Abstract][Full Text] [Related]
37. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
38. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
[TBL] [Abstract][Full Text] [Related]
39. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
Patel YC; Srikant CB
Endocrinology; 1994 Dec; 135(6):2814-7. PubMed ID: 7988476
[TBL] [Abstract][Full Text] [Related]
40. The effects of somatostatin analogs on biochemical parameters in acromegaly.
Liuzzi A; Marzullo P
J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
